1.

Dr Gorana Matovina-Brko Klinika za internu onkologiju  Institut za onkologiju Vojvodine, Sremska Kamenica,

dr Gorana Matovina Brko, zaposlena na Klinici za internu onkologiju  Instituta za onkologiju Vojvodine, Sremska Kamenica,

rođena: 2.06.1978, Novi Sad, Srbija,

BRAČNI STATUS: udata, dvoje dece: 2009. i 2011.

OBRAZOVANJE:

Unvirezitet:

Medicinski fakultet, Uiverzitet u Novom Sadu diplomirala marta 2005, prosečna ocena  9,87.

Kvalifikacija: Doktor medicine (2005),

Doktorske studije:

Univerzitet u Novom Sadu, Medicinski fakultet: Oktobar 2007: status: Student treće godine

Specijalizacije interne medicine: Medicinski fakultet, Univerzitet u Novom Sadu, decembar 2014. Specijalista interne medicine

Subspecijalističke studije ONKOLOGIJA: Medicinski fakultet, Univerzitet u Novom Sadu, maj 2020.

RADNO ISKUSTVO:

2006-2008. Institut za onkologiju Vojvodine, Klinika za internu onkologiju: Klinički lekar,

2008-2014. Institut za onkologiju Vojvodine, Klinika za internu onkologiju: lekar na specijalizaciji iz interne medicine

2014- 2017: Specijalista interne medicine: Odsek za endokrine tumore i tumore dojke: Institut za onkologiju Vojvodine, Klinika za internu onkologiju

2017- 2022: Specijalista interne medicine: Šef odseka za transplantaciju matičnih ćelija: Institut za onkologiju Vojvodine, Klinika za internu onkologiju

2006 – 2017.: Medicinski fakultet, Univerzitet u Novom Sadu, Katedra za onkologiju: Asistent

BROJ LICENCE : 203865 izdata oktobra 2008.
obnovljena 01.12. 2015.

UČEŠĆE U PROJEKTIMA: Pokrajinski naučni projekat “Chemo brain”

ISKUSTVO U KLINČIKIM STUDIJAMA: (podistraživač I glavni istraživač faza 2 i 3):

ČLANSTVO U UDRUŽENJIMA

Srpsko lekarsko društvo

Društvo lekara Vojvodine

UMOS Udruženje medikalnih onkologa Srbija (Udruženje mladih onkologa do 2018.)

Evropsko udruženje medikalnih onkologa ESMO.

Francusko srpsko onkološko udruženje: organizacioni komitetet Francusko srpskog onkološkog kongresa: 2015, 2016, 2017, 2018, 2019,2020,2022.

OBLASTI INTERESOVANJA: karcinom dojke, karcinom prostate, karcinom mokraćne bešike, karcinom bubrega, imunoterapija.

JEZICI:

engleski – tečno,

nemački – bazično,

slovački jezik – bazično.

LISTA PUBLIKACIJA:

KNJIGE:

  • Cvetanovic A, Popovic L, Zivkovic N, Matovina-Brko G, Filipovic S, Kostic M, Vrbic S, Pejcic I Immune Checkpoint Inhibitors in the Treatment of Solid Tumors: A New Key in the Hands of Oncologists in Watanabe HS Horizons in Cancer Research Vol 65 Nova Science Publishing 2017 ISBN: 978-1-53610-954-2
  • Matovina-Brko G, Popovic L Karcinom dojke I gojaznost u Stokic E. Gojaznost je bolest koja se leči (drugi deo) 2018 Medicinski fakultet Novi Sad ISBN 978-86-7197-549-0

PUBLIKACIJE:

  1. Popovic M, Matovina-Brko G, Jovic M, Popovic LS. Immunotherapy: A new standard in the treatment of metastatic clear cell renal cell carcinoma. World J Clin Oncol. 2022 Jan 24;13(1):28-38.
  2. Matovina Brko G, Popovic M, Jovic M, Radic J, Bodlovic Kladar M, Nikolic I, Vidovic V, Kolarov Bjelobrk I, Kukic B, Salma S, Litavski J, Petrovic N, Vranjkovic B, Roganovic T, Ruzic M, Dugandzija T, Popovic L. COVID-19 vaccines and cancer patients: acceptance, attitudes and safety. J BUON. 2021 Sep-Oct;26(5):2183-2190.
  3. Popovic LS, Matovina-Brko G, Popovic M, Popovic M, Cvetanovic A, Nikolic I, Kukic B, Petrovic D. Immunotherapy in the treatment of lymphoma. World J Stem Cells. 2021 Jun 26;13(6):503-520.
  4. Popovic M, Matovina-Brko G, Petrovic D, Vranjkovic B, Boskovic-Milosevic B,Popovic L. Prognostic value of age-adjusted international prognostic index in patients with relapsed or refractory diffuse large b-cell lymphoma-single centre experience. 2nd Regional congress of medical oncology, Belgrade , Serbia, May 16-18 th 2019. Archive of Oncol 2019;25(suppl 1) p3.
  5. Matovina-Brko G, Popovic M, Trifunovic J, Pesic J, Popovic L. First line treatment of HR+/HER- metastatic breast cancer. 2 nd Regional congress of medical oncology, Belgrade, Serbia , May 16-18 th 2019. Archive of Oncol 2019;25(suppl 1) p 35.
  6. Matovina-Brko G, Popovic L, Popovic M. Immune-related adverse event, 10 th French Serbian Oncology Congress, Novi Sad. 7-9 March 2019, p 44.
  7. Popovic L, Tomasevic Z, Stamatovic L, Markovic I, Matovina-Brko G, Buta M, Golubovic A, Selakovic V, Trifunovic J, Mutrezani Z, Ivanovic N, Nedovic J, Ninkovic S, Filipovic S, Cvetanovic A, Djordjevic N, Karanikolic A, Ivkovic-Kapic T, Vicko F. Serbian consensus of neoadjuvant therapy for breast cancer: NeoPULSE. J BUON. 2018 Mar-Apr;23(2):522-532.
  8. Susnjar S, Popovic L, Cvetanovic A, Stanic N, Citic J, Kolarov-Bjelobrk I, Popovic M, Nedovic N, Stojanovic A, Matovina-Brko G, Serovic K. Real world data: Trastuzumab w/o concurrent endocrine therapy in luminal HER2-positive metastatic breast cancer resulted in decreased overall survival. European Journal of Cancer. 2018 Apr 1;92:S112.
  9. Popovic L, Matovina-Brko G, Popovic M, Petrovic D, Cvetanovic A, Vukojevic J, Jovanovic D  High dose chemotherapy with stem cell support in the treatment of testicular cancer. World J Stem Cells. 2015 Dec 26;7(11):1222-32.
  10. Popovic L, Matovina-Brko G, Popovic M. Checkpoint inhibitors in the treatment of urological malignancies. ESMO Open. Volume 2, Issue 2, 2017.
  11. Cvetanovic A, Popovic L, Filipovic S, Trifunovic J, Zivkovic N, Matovina-Brko G, Kostic M; Vicko F, Kocic B, Kolarov-Bjelobrk I Young Age and Pathological Features Predict Breast Cancer Outcome-report from a Dual Institution Expirience in Serbia J BUON 2015 Nov-Dec;20(6):1407-13.
  12. markovic O, Popović L, Marisavljevic D, Hajder J, Živković R, Stanisavljevic N, Jovanovic D,  Filipovic B, Stanisavljevic D, Matovina-Brko G, Matkovic T, Todorović M, Petrovic D, Mihaljevic B. Prognostic Impact Analysis of absolute lymphocyte count (ALC) and absolute monocyte count (AMC) in patients with Diffuse Large B-Cell Lymphoma 3rd Congress of Hematologist Serbia 2015 OP23: 122
  13. Popovic L, Matovina-Brko G. Anti-PD1/PD-L1 checkpoint inhibitors: a new frontier in cancer immunotherapy The second congress of the Serbian association for cancer research Proceedings book 2015 OP04: 14-17
  14.  Popovic L, Jovanovic D, Knezevic-Usaj S, Nikin Z, Popovic Dj, Matovina-Brko G, Popovic M, Petrovic D The Expression of Molecular Markers As a Prognostic Factor of Diffuse Large B-Cell Lymphoma Treatment in Rituximab Era 1st ESHInternational Conference on New Concepts in B Cell Malignancies: From Molecular Pathogenesis to Personilized Treatment Abstr 2292 2014.
  15. Ružić M, Fabri M, Preveden T, Stojanović S, Milošević Z, Matovina-Brko G. Hepatocellular carcinoma in patients with chronic hepatitis C: Experience gained at Clinical Center of Vojvodina. Medicinski pregled 67 (suppl. 2), 31-38
  16. Popovic L., Jovanovic D., Petrovic D., Nikin Z., Matovina-Brko G., Trifunovic J., Kolarov-Bjelobrk I. Concurrent Chronic Lymphocytic Leukemia And Merkel Cell Carcinoma In Primary Skin Tumor And Metastatic Lymph Node Indian J Hematol Blood Transfus 2014 Sep;30(Suppl 1):422-4.
  17. Popovic L, Trifunovic J, Pesic J, MatovinaBrko G, Kolarov-Bjelobrk I, Memisevic N, Jovanovic D Male Breast Cancer In The Era Of Modern Therapies: Serbian Single Centre Experience Report Breast J 2014 Apr 8. May;20(3):329-30
  18. Markovic O, Popović L, Marisavljevic D, Hajder J, Živković R, Stanisavljevic N, Jovanovic D,  Filipovic B, Stanisavljevic D, Matovina-Brko G, Matkovic T, Todorović M, Petrovic D, Mihaljevic B. Comparison of prognostic impact of absolute lymphocyte count (ALC), absolute monocyte count (AMC), ALC/AMC prognostic score and ALC/AMC ratio in patients with diffuse large B cell lymphoma Eur J Intern Med 2014 Mar;25(3):296-302.
  19. Gorana Matovina-Brko, Maja Ružić, Milotka Fabri, Lazar Popović, Ivana Kolarov-Bjelobrk, Jasna Trifunović. HEPATITIS B REACTIVATION AFTER THERAPY FOR NON-HODGKIN LYMPHOMA: A CASE REPORT WITH REVIEW OF LITERATURE. Archive of Oncology 2013.  21 ( 3-4) : 151-154.
  20. Popovic L, Markovic O, Jovanovic D, Marisavljevic D, Petrovic D, Mihaljevic B, Nikin Z, Matkovic T, MatovinaBrko G, Zivkovic R.  Differences in baseline characteristics and survival rates between GCB and non-GCB diffuse large B-cell lymphoma treated with rituximab based immunochemotherapy EJC Suppl 2013 ECCO-ESMO abstract 3629
  21. Popovic L, Markovic O, Jovanovic D, Marisavljevic D, Petrovic D, Mihaljevic B, Nikin Z, Matkovic T, MatovinaBrko G, Zivkovic R.  CD5-positive versus CD5-negative diffuse large B-cell lymphoma treated with immunochemotherapy: Is there a difference? EJC Suppl 2013 ECCO-ESMO abstract 3630
  22. Popovic L, Nikin Z, Jovanovic D, Knezevic-Usaj S, Popovic M, MatovinaBrko G. BAFF, TACI and BCMA receptors expression and their impact on survival of patients with diffuse large b-cell lymphoma EJC Suppl 2013 ECCO-ESMO abstract 3633
  23. Matovina-Brko G., Ruzic M., Fabri M., Popovic L., Kolarov-Bjelobrk I., Trifunovic J., Petkovic D. Treatment of acute hepatitis C in breat cancer patient J chemother 2014 Jun;26(3):180-3
  24. MatovinaBrko G, Nikolin B, Popovic L, Nikin Z, Jovanovic D, Popovic-Petrovic S. Paratesticular rhabdomyosarcoma of a young adult: a case report with review of the literature. Contemp Oncol (Pozn) 2015; 19 (3): 252–256
  25. Markovic O,Popovic L, Marisavljevic D, Jovanovic D, Mihaljevic B, Stanisavljevic D, Hajder J, Zivkovic R, Petrovic D, Stanisavljevic N, MatovinaBrko G, Todorovic M, Bila J Prognostic Significance Of Low Lymphocytes Count In The Patients With Diffuse Large B Cell Lymphoma (DLBCL) Haematologica 2013 (EHA Abstract)
  26.  Petrovic-Popovic S, Tomic S, Nedeljkovic M, Popovic L, Matovina G. Early rehabilitation in patients with breast carcinoma Vojnosanit Pregl. 2013 Apr;70(4):407-10
  27.  Popovic L, Jovanovic D, Petrovic D, Petrovic N, Sundji A, Roganovic T,  MatovinaBrko G. Significance of Standard Prognostic Scores (IPI and R-IPI) in Prognosis of Diffuse Large B-cell Lymphoma Patients treated with Immunochemotherapy 2nd Serbian Heamatology Congress/6th Balkan Day of Haematology Abstract Book Nov 2011:173.
  28. Popovic L, Jovanovic D, Petrovic D, Matovina G, Roganovic T. ALK-negative large cells lymphoma in sceletal muscle-case report. Medicina Danas 2009; 8(7-9): 249-54. (serbian)
  29. Popovic L, Jovanovic D, Petrovic D, Matovina G, Roganovic T. „Rituximab in combination with chemotherapy in treatment of diffuse large B-cell lymphoma: our expirience“Abstr.33 Bilt. Hematol 2007; 35(3): 86-100  (serbian)
  30. Popovic L, Jovanovic D, Petrovic D, Matovina G, Roganovic T. „Breast involving lymphoma: report of four cases“ Abstr. 35 Bilt. Hematol 2007; 35(3): 86-100 (serbian)
  31. Popovic L, Jovanovic D, Petrovic D, Matovina G, Roganovic T. „ALK-negative anaplastic large T-cell lymphoma in a muscle: case report and review of literature“ Abstr. 44 Bilt. Hematol 2007; 35(3): 86-100  (serbian)
  32. Matovina G, Jovanovic D, Fabri M, Petrovic D, Popovic L, Roganovic T. „Hepatitis B viral infection reactivation during induction lymphoma therapy: report of two cases“ Abstrakt br. 54 Bilt. Hematol 2007; 35(3): 86-100  (serbian)
  33. Popovic L, Popovic M, Matovina-Brko B, Petrovic D. [Interim PET/CT(PET2) u prognozi lečenja Hodžinovog limfoma, IV Kongres hematologa Srbije, Niš. 17-20 Okt 2019, p 101. ]
  34. Popovic L, Popovic M, Matovina-Brko B, Petrovic D. [Relaps /refraktorni difuzni B-krupnoćelijski limfom-bolest lose prognoze: desetogodišnje iskustvo Instituta za onkologiju Vojvodine, IV Kongres hematologa Srbije, Niš. 17-20 Okt 2019, p127.]
  35. Popovic L, Popovic M, Matovina-Brko B, Petrovic D. [Terapija održavanja rituksimabom kao najznačajniji factor predikcije dugotrajne remisije kod bolesnika sa folikularnim limfomom, IV Kongres hematologa Srbije, Niš. 17-20 Okt 2019, p 128.]

 

 

Other Members